Clinical Trials Logo

Clinical Trial Details — Status: No longer available

Administrative data

NCT number NCT03014440
Other study ID # 13-010562
Secondary ID
Status No longer available
Phase N/A
First received January 5, 2017
Last updated March 30, 2017

Study information

Verified date March 2017
Source Children's Hospital of Philadelphia
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. Pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. There are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. There are no well-documented studies and completely analyzed data for pediatric epileptic patients.


Recruitment information / eligibility

Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 1 Year to 20 Years
Eligibility Inclusion Criteria:

1. Ages between 1 year old and 20 years old, male or female at the first visit, Week -4 (at time informed consent form is signed)

2. Documentation of a diagnosis of drug-resistant epilepsy as proven by and documented with medical records and/or the following clinical features (must have all 3 of the following):

1. Failure to control seizures despite appropriate trial of 3 or more AEDs at therapeutic doses

2. An intractable childhood epilepsy including, Dravet Syndrome or Lennox-Gastaut Syndrome

3. Must report at least 3 countable (non-countable seizures includes absence and myoclonic) seizures per month

3. Between 1-3 baseline AEDs . Vagus nerve stimulator (VNS), ketogenic diet, and modified Atkins diet do not count towards this limit.

4. VNS must be on stable settings for a minimum of 3 months.

5. If on the ketogenic diet, must be on stable ratio for a minimum of 3 months.

Exclusion Criteria:

1. Epilepsies associated with neurodegenerative diseases, including neuronal ceroidolipofuscinosis, progressive myoclonus epilepsies, Rasmussen encephalitis, and tumors

2. Epilepsies associated with an inborn error of metabolism, including mitochondrial disorders

3. Felbatol initiated within the past 12 months

4. Use of any Cannabis-related product (including hemp oil) in the past 12 months as assessed by parental questioning.

5. Laboratory values on comprehensive metabolic panel (CMP) and complete blood count (CBC) testing that are Class 3 or higher according to the CTCAE v4.0.

6. Positive pregnancy test.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cannabidiol


Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Eric Marsh, MD Children's Hospital of Pittsburgh, Geisinger Clinic
See also
  Status Clinical Trial Phase
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05928598 - Goals for Epilepsy Clinic Visits Trial N/A
Recruiting NCT05539287 - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy Phase 2
Not yet recruiting NCT04601974 - Lentiviral Gene Therapy for Epilepsy Phase 1/Phase 2
Completed NCT02982824 - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy N/A
Recruiting NCT05485558 - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy Phase 2
Not yet recruiting NCT04553354 - Cortical Resections in Drug Resistant Epilepsy
Recruiting NCT04999046 - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy N/A
Recruiting NCT04714996 - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy Phase 2
Recruiting NCT04839601 - RNS System RESPONSE Study N/A
Recruiting NCT06059157 - Epileptogenic Network Visualisation With Advanced MRI N/A
Recruiting NCT05947656 - Evaluation of the NaviFUS System in Drug Resistant Epilepsy N/A
Recruiting NCT05393518 - Electroclinical Correlation of Anxiety N/A
Not yet recruiting NCT05555537 - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed NCT03419000 - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY N/A
Enrolling by invitation NCT06341075 - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy N/A
Not yet recruiting NCT05527093 - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy N/A
Recruiting NCT05697614 - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children Phase 4
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT06432907 - StereoEEG Motor Neuronal Potentials Decoding N/A